Cardiff Oncology (CRDF) Cost of Revenue (2016 - 2018)
Cardiff Oncology (CRDF) has disclosed Cost of Revenue for 6 consecutive years, with $26677.0 as the latest value for Q3 2018.
- Quarterly Cost of Revenue fell 94.36% to $26677.0 in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $26677.0 through Jun 2019, down 98.13% year-over-year, with the annual reading at $597457.0 for FY2018, 67.02% down from the prior year.
- Cost of Revenue hit $26677.0 in Q3 2018 for Cardiff Oncology, down from $204436.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $6.0 million in Q4 2015 to a low of $15441.0 in Q4 2014.
- Historically, Cost of Revenue has averaged $653212.0 across 5 years, with a median of $374968.5 in 2017.
- Biggest five-year swings in Cost of Revenue: tumbled 95.87% in 2014 and later skyrocketed 38845.57% in 2015.
- Year by year, Cost of Revenue stood at $15441.0 in 2014, then surged by 38845.57% to $6.0 million in 2015, then tumbled by 90.24% to $587219.0 in 2016, then plummeted by 34.68% to $383593.0 in 2017, then tumbled by 93.05% to $26677.0 in 2018.
- Business Quant data shows Cost of Revenue for CRDF at $26677.0 in Q3 2018, $204436.0 in Q2 2018, and $366344.0 in Q1 2018.